Stockscreener 앱 받기
8.21
0.24%
-0.02
시간 외 거래:
8.10
-0.11
-1.34%
Ginkgo Bioworks Holdings Inc 주식(DNA)의 최신 뉴스
Ginkgo Bioworks (DNA) director Henry Christian O receives 25,000 RSU equity grant - Stock Titan
Director Ross Fubini receives 25,000 RSUs at Ginkgo Bioworks (NYSE: DNA) - Stock Titan
Director at Ginkgo Bioworks (NYSE: DNA) granted 25,000 RSUs - Stock Titan
Ginkgo Bioworks (DNA) director Harry Sloan awarded 25,000 RSUs - Stock Titan
Ginkgo Bioworks Holdings, Inc. Files Form 8-K With SEC for June 2026 – Key Submission Details and Company Information 17 – Minichart - Minichart
Ginkgo Bioworks (NYSE: DNA) shareholders approve directors, Deloitte and executive pay - Stock Titan
Ginkgo Bioworks (DNA) Short Interest & Short Float | Updated Jun 2026 $DNA - MarketBeat
Austin Che (DNA) files Form 144 showing sales totaling tens of thousands of Class A shares - Stock Titan
Precision Trading with Ginkgo Bioworks Holdings Inc. Class A (DNA) Risk Zones - Stock Traders Daily
Ginkgo Bioworks Holdings, Inc. - MLQ.ai
Top Ginkgo Bioworks (DNA) Competitors 2026 - MarketBeat
Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Ginkgo Bioworks Holdings, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Significant Losses to Contact the Firm - TMX Newsfile
Technical Reactions to DNA Trends in Macro Strategies - Stock Traders Daily
Ginkgo Bioworks (NYSE: DNA) insider logs RSU vesting and small tax-related share sale - Stock Titan
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery - Investing News Network
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One™: a High-Throughput ADME Platform That Brings Pharmacokinetic Projection Earlier in Drug Discovery - marketscreener.com
Ginkgo Bioworks, Tangible Scientific, And Inductive Bio Launch ADME-One High-Throughput ADME Platform - marketscreener.com
New AI lab service aims for fewer dead ends in drug discovery - Stock Titan
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Dips While Market Gains: Key Facts - MSN
Ginkgo Bioworks Holdings (DNA) Price Target Decreased by 11.11% to 10.88 - MSN
Steve Coen (DNA) files Form 144 to sell 307 Class A shares - Stock Titan
Ginkgo Bioworks Holdings Inc (DNA): What’s the Future of Autonomous Lab? - Yahoo Finance
DNA Technical Analysis | Trend, Signals & Chart Patterns | GINKGO BIOWORKS HOLDINGS INC (NYSE:DNA) - ChartMill
Trading the Move, Not the Narrative: (DNA) Edition - Stock Traders Daily
Ginkgo Bioworks Announces Presentations at the Upcoming American - GuruFocus
Viking Global (DNA) reports 3,577,128 shares, removes retired reporting person - Stock Titan
Ginkgo Bioworks Holdings, Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:DNA) 2026-05-13 - Seeking Alpha
Ginkgo Bioworks slumps 14% after projecting FY26 cash burn of $125M-$150M - MSN
Ginkgo outlines $125M-$150M 2026 cash burn guidance while expanding Nebula to 103 racks - MSN
Ginkgo Bioworks: Another Lost Year (NYSE:DNA) - Seeking Alpha
Austin Che files Form 144 to sell Class A shares (NASDAQ: DNA) - Stock Titan
These Analysts Think Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Sales Are Under Threat - 富途牛牛
The Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Sales Forecasts - Yahoo Finance
The $59B Quiet Shift Reshaping How Patients Access Care - Benzinga
How The Ginkgo Bioworks (DNA) Story Is Shifting After The Biosecurity Divestiture And Target Cut - Yahoo Finance
William Blair Maintains Ginkgo Bioworks(DNA.US) With Sell Rating - Moomoo
TradingKey - TradingKey
Number of shareholders of Ginkgo Bioworks Holdings Inc. – OTC:DNABW - TradingView
Ginkgo Bioworks Q1 Earnings Call Highlights - Barchart.com
Ginkgo Bioworks Earnings Call: Cash Rich, Revenue Pinched - TipRanks
DNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2026 Earnings Call Transcript - Insider Monkey
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Price, News, Quote & History - Yahoo Finance
Ginkgo Bioworks slumps 14% after projecting FY26 cash burn of $125M-$150M (DNA:NYSE) - Seeking Alpha
TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating Challenging Waters with a Pioneering Vision - DirectorsTalk Interviews
Ginkgo Bioworks Previously Reported Fincl Results for Comparable Periods Retrospectively Recast >DNA - Moomoo
Earnings call transcript: Ginkgo Bioworks Q1 2026 sees revenue drop, restructuring efforts noted - Investing.com Canada
Ginkgo Bioworks : Q1 2026 Results (Dial-In Information) - marketscreener.com
1.27%
1.43%
자본화:
|
볼륨(24시간):